CTRI/2023/10/059034
Not Yet Recruiting
Phase 3
Effect of Dapagliflozin and Metformin Combination on Insulin Resistance and Cardiovascular Disease Risk Factors in Drug Naïve Type II Diabetes Mellitus Patients in a Tertiary Care Hospital: An Open Label Randomized Controlled Trial - NI
S Abissha0 sites0 target enrollmentTBD
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Health Condition 1: E118- Type 2 diabetes mellitus with unspecified complications
- Sponsor
- S Abissha
- Status
- Not Yet Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) Male/female aged 18\-60 years
- •2\) Newly diagnosed with type 2 diabetes mellitus patients (FBS \>126mg/dl and PPBS \>200mg/dl)
- •3\) HbA1c level 7% to 8%
- •4\) Newly diagnosed type II diabetes with or without hypertension and dyslipidemia
Exclusion Criteria
- •1\) Diabetes with renal failure
- •2\) Diabetes with liver failure
- •3\) Pregnancy and lactation, psychiatric patients
- •4\) Age above 60 years
- •5\) Patients who are not willing to give informed consent
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not Yet Recruiting
Phase 4
Comparative effects of dapagliflozin and metformin in obese diabetic patientsHealth Condition 1: E116- Type 2 diabetes mellitus with other specified complicationsCTRI/2023/11/059814 Shobana
Active, Not Recruiting
Phase 1
Effects of glucose-lowering interventions in pre-diabetesEUCTR2015-001552-30-DKSteno Diabetes Center A/S160
Recruiting
N/A
Dapagliflozin add-on to metformin therapy in diabetic patientsCTRI/2022/12/048622Aditya kumar
Completed
Phase 1
Drug Interaction With MetforminHealthy Male and Female SubjectsNCT00546741AstraZeneca18
Recruiting
N/A
Effects of dapaglifrogine and metoformine in patients with type 2 diabetes:a randomized controlled studyType 2 diabetesJPRN-UMIN000032296Yokohama City University100